These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32102629)

  • 1. Redefined Measure of Early Neurological Improvement Shows Treatment Benefit of Alteplase Over Placebo.
    Agarwal S; Scher E; Lord A; Frontera J; Ishida K; Torres J; Rostanski S; Mistry E; Mac Grory B; Cutting S; Burton T; Silver B; Liberman AL; Lerario MP; Furie K; Grotta J; Khatri P; Saver J; Yaghi S
    Stroke; 2020 Apr; 51(4):1226-1230. PubMed ID: 32102629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Redefining Early Neurological Improvement After Reperfusion Therapy in Stroke.
    Agarwal S; Cutting S; Grory BM; Burton T; Jayaraman M; McTaggart R; Reznik M; Scher E; Chang AD; Frontera J; Lord A; Rostanski S; Ishida K; Torres J; Furie K; Yaghi S
    J Stroke Cerebrovasc Dis; 2020 Feb; 29(2):104526. PubMed ID: 31836356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-hour improvement of patients in the National Institute of Neurological Disorders and Stroke trials and prediction of final outcome.
    Hemmen TM; Ernstrom K; Raman R
    Stroke; 2011 Nov; 42(11):3163-7. PubMed ID: 21868741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials.
    Ramakrishnan TCR; Kumaravelu S; Narayan SK; Buddha SS; Murali C; Majeed PHA; Meenakshi-Sundaram S; Wadia RS; Sharma V; Basu I; Vijaya P; Salam KA; Barmare S; Vaid Z; Nirmal Raj KK; Wattamwar PR; Asokan K; Dhonge V; Nellikunja S; Namjoshi D; Srinivasa R; Laddhad DS; Deshpande SD; Raghunath B; Kalita J; Kumar M; Misra UK; Pradeep M;
    Am J Cardiovasc Drugs; 2018 Oct; 18(5):387-395. PubMed ID: 29948822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of long-term outcome by percent improvement after the first day of thrombolytic treatment in stroke patients.
    Nam HS; Lee KY; Han SW; Kim SH; Lee JY; Ahn SH; Kim DJ; Kim DI; Nam CM; Heo JH
    J Neurol Sci; 2009 Jun; 281(1-2):69-73. PubMed ID: 19304298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.
    Khatri P; Kleindorfer DO; Devlin T; Sawyer RN; Starr M; Mejilla J; Broderick J; Chatterjee A; Jauch EC; Levine SR; Romano JG; Saver JL; Vagal A; Purdon B; Devenport J; Pavlov A; Yeatts SD;
    JAMA; 2018 Jul; 320(2):156-166. PubMed ID: 29998337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of early National Institutes of Health Stroke Scale improvement with vessel recanalization and functional outcome after intravenous thrombolysis in ischemic stroke.
    Kharitonova T; Mikulik R; Roine RO; Soinne L; Ahmed N; Wahlgren N;
    Stroke; 2011 Jun; 42(6):1638-43. PubMed ID: 21512176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated-measures analysis of the National Institute of Neurological Disorders and Stroke rt-PA stroke trial.
    Feng W; Vasquez G; Suri MF; Lakshminarayan K; Qureshi AI
    J Stroke Cerebrovasc Dis; 2011; 20(3):241-6. PubMed ID: 20621509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
    Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
    JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute Ischemic Stroke with Very Early Clinical Improvement: A National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trials Exploratory Analysis.
    Balucani C; Levine SR; Khoury JC; Khatri P; Saver JL; Broderick JP
    J Stroke Cerebrovasc Dis; 2016 Apr; 25(4):894-901. PubMed ID: 26825352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.
    Mori M; Naganuma M; Okada Y; Hasegawa Y; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Kario K; Okuda S; Koga M; Minematsu K; Toyoda K
    Cerebrovasc Dis; 2012; 34(2):140-6. PubMed ID: 22854333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of major neurological improvement after intravenous thrombolysis in acute ischemic stroke: a hospital-based study from south India.
    Boddu DB; Srinivasarao Bandaru VC; Reddy PG; Madhusudan M; Rukmini MK; Suryaprabha T; Jabeen SA; Suvarna A; Jayalakshmi SS; Meena AK; Borgohain R; Kaul S
    Neurol India; 2010; 58(3):403-6. PubMed ID: 20644268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Percent change on the National Institutes of Health Stroke Scale: a useful acute stroke outcome measure.
    Bruno A; Saha C; Williams LS
    J Stroke Cerebrovasc Dis; 2009 Jan; 18(1):56-9. PubMed ID: 19110146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early neurologic improvement based on the National Institutes of Health Stroke Scale score predicts favorable outcome within 30 minutes after undergoing intravenous recombinant tissue plasminogen activator therapy.
    Takagi T; Kato T; Sakai H; Nishimura Y
    J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):69-74. PubMed ID: 23164483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke.
    Brown DL; Johnston KC; Wagner DP; Haley EC
    Stroke; 2004 Jan; 35(1):147-50. PubMed ID: 14657446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-dependence of NIHSS in predicting functional outcome of patients with acute ischemic stroke treated with intravenous thrombolysis.
    Wu Z; Zeng M; Li C; Qiu H; Feng H; Xu X; Zhang H; Wu J
    Postgrad Med J; 2019 Apr; 95(1122):181-186. PubMed ID: 30975729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the National Institute of Neurological Disorders and Stroke tissue plasminogen activator studies following European Cooperative Acute Stroke Study III patient selection criteria.
    Hemmen TM; Rapp KS; Emond JA; Raman R; Lyden PD
    J Stroke Cerebrovasc Dis; 2010; 19(4):290-3. PubMed ID: 20471855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators.
    Clark WM; Albers GW; Madden KP; Hamilton S
    Stroke; 2000 Apr; 31(4):811-6. PubMed ID: 10753980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Could clinical diffusion-mismatch determined using DWI ASPECTS predict neurological improvement after thrombolysis before 3 h after acute stroke?
    Terasawa Y; Kimura K; Iguchi Y; Kobayashi K; Aoki J; Shibazaki K; Kaji R
    J Neurol Neurosurg Psychiatry; 2010 Aug; 81(8):864-8. PubMed ID: 20562433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Alteplase on Treatment of Acute Single Small Subcortical Infarction.
    Marcelinus K; Liu H; Zhang K; Zong C; Yang H; Song B; Gao Y; Xu Y
    Curr Neurovasc Res; 2022; 19(3):255-266. PubMed ID: 36043775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.